Status:
COMPLETED
Identifying Factors That Predict Antidepressant Treatment Response
Lead Sponsor:
Emory University
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This study will compare different treatments for depression in order to identify which factors predict effectiveness, and will include a companion study which investigates combining treatments and lon...
Detailed Description
Major depressive disorder (MDD) is a serious illness that affects a person's body, mood, and thoughts. The symptoms of MDD can interfere with a person's ability to work, study, sleep, eat, and enjoy a...
Eligibility Criteria
Inclusion
- Current DSM-IV diagnosis of major depressive episode, as determined by Structured Clinical Interview for DSM-IV (SCID-IV)
- Primary diagnosis of MDD, based on prominence of symptoms and target for intervention (comorbid anxiety disorders, except obsessive-compulsive disorder (OCD), will not be criteria for exclusion)
- Score of at least 18 on the 17-item Hamilton Rating Scale for Depression (HAM-D17)
- Agrees to use an effective form of contraception and/or double barrier method
Exclusion
- Previously treated for major depression with either medication or psychotherapy
- Current psychosis, dementia, eating disorder, or dissociative disorder
- History of bipolar disorder (I and II) or schizophrenia
- Alcohol or drug dependence within 3 months prior to study entry or current alcohol or drug abuse (excluding nicotine and caffeine), as assessed by medical history and urine drug screening
- Requires neuroleptic or mood stabilizer therapy in addition to depression treatment
- Presence of any acute or chronic medical disorder that could affect successful completion of the trial
- Medical contraindications that would preclude treatment with escitalopram or duloxetine
- Presence of practical issues that would likely prevent completion of the study (e.g., planned geographical relocation)
- Pregnant or breastfeeding
- Medical conditions that could prevent the safe use of MRI (e.g., pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, or other implants; steel worker)
- Medical conditions that could prevent the safe completion of a dexamethasone-corticotropin releasing factor (Dex-CRF) test (e.g., uncontrolled hypertension, significant abnormalities in EKG, anemia, known allergies against drugs)
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2015
Estimated Enrollment :
344 Patients enrolled
Trial Details
Trial ID
NCT00360399
Start Date
August 1 2006
End Date
April 1 2015
Last Update
August 30 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Mood and Anxiety Disorders Program
Atlanta, Georgia, United States, 30306
2
Emory University School of Medicine
Atlanta, Georgia, United States, 30322